Linagliptin
Brand: Tradjenta (US/EU) / Trajenta (IN) / Linapta (BD)
Antidiabetic
DPP-4 inhibitor
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 2 h |
| Bioavailability | 30 % (approx) |
| Protein Binding | 70 % |
| Volume of Distribution | 1 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | No renal dose adjustment required; very low hypoglycemia risk when not combined with SU/insulin. |
⚠️ Safety & Warnings
Severity: Mild
Adverse Effects:
Nasopharyngitis, cough, rare pancreatitis, joint pain
Contraindications:
Known hypersensitivity
Precautions:
Advise to report severe abdominal pain (pancreatitis); monitor if combined with SU (additive hypo risk)